Artelo Biosciences Gets FDA Clearance for Phase 1 Peripheral Neuropathy Study

MT Newswires Live07-15

Artelo Biosciences (ARTL) said Monday it has received a "Study May Proceed" notification from the US Food and Drug Administration regarding its investigational new drug application for ART26.12 to potentially treat chemotherapy-induced peripheral neuropathy.

With the FDA clearance, a phase 1 single ascending dose study in humans may proceed, with the results expected in the first half of 2025, the company said, adding that study startup activities have started in collaboration with Worldwide Clinical Trials.

ART26.12, the lead compound in the company's fatty acid binding protein platform, is being developed as a non-opioid treatment for neuropathy, the company said.

Shares of Artelo Biosciences were up more than 3% in recent Monday trading.

Price: 1.33, Change: +0.04, Percent Change: +3.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2451699629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-15 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451699629","market":"sh","top_or_hot":-1,"title":"Artelo Biosciences Gets FDA Clearance for Phase 1 Peripheral Neuropathy Study","media":"MT Newswires Live","content":"<html><body><p> Artelo Biosciences (ARTL) said Monday it has received a \"Study May Proceed\" notification from the US Food and Drug Administration regarding its investigational new drug application for ART26.12 to potentially treat chemotherapy-induced peripheral neuropathy.</p><p>With the FDA clearance, a phase 1 single ascending dose study in humans may proceed, with the results expected in the first half of 2025, the company said, adding that study startup activities have started in collaboration with Worldwide Clinical Trials.</p><p>ART26.12, the lead compound in the company's fatty acid binding protein platform, is being developed as a non-opioid treatment for neuropathy, the company said.</p><p>Shares of Artelo Biosciences were up more than 3% in recent Monday trading.</p><p>Price: 1.33, Change: +0.04, Percent Change: +3.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artelo Biosciences Gets FDA Clearance for Phase 1 Peripheral Neuropathy Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtelo Biosciences Gets FDA Clearance for Phase 1 Peripheral Neuropathy Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-15 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artelo Biosciences (ARTL) said Monday it has received a \"Study May Proceed\" notification from the US Food and Drug Administration regarding its investigational new drug application for ART26.12 to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARTL","symbol_name":"Artelo Biosciences, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2451699629","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451699629","pubTimestamp":1721054282,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Artelo Biosciences  said Monday it has received a \"Study May Proceed\" notification from the US Food and Drug Administration regarding its investigational new drug application for ART26.12 to potentially treat chemotherapy-induced peripheral neuropathy.With the FDA clearance, a phase 1 single ascending dose study in humans may proceed, with the results expected in the first half of 2025, the company said, adding that study startup activities have started in collaboration with Worldwide Clinical Trials.ART26.12, the lead compound in the company's fatty acid binding protein platform, is being developed as a non-opioid treatment for neuropathy, the company said.Shares of Artelo Biosciences were up more than 3% in recent Monday trading.Price: 1.33, Change: +0.04, Percent Change: +3.10","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARTL":"Artelo Biosciences, Inc.","BK4007":"制药"},"translate_title":"Artelo Biosciences获得FDA 1期周围神经病变研究许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTL":0.9},"content_text":"Artelo Biosciences (ARTL) said Monday it has received a \"Study May Proceed\" notification from the US Food and Drug Administration regarding its investigational new drug application for ART26.12 to potentially treat chemotherapy-induced peripheral neuropathy.With the FDA clearance, a phase 1 single ascending dose study in humans may proceed, with the results expected in the first half of 2025, the company said, adding that study startup activities have started in collaboration with Worldwide Clinical Trials.ART26.12, the lead compound in the company's fatty acid binding protein platform, is being developed as a non-opioid treatment for neuropathy, the company said.Shares of Artelo Biosciences were up more than 3% in recent Monday trading.Price: 1.33, Change: +0.04, Percent Change: +3.10","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451699629"}